R&D expenses
The latest news about R&D expenses: headlines, AI summaries and the full story from every source.
- MiNK Therapeutics Reports Q3 2026 Financial Results and Clinical Updates
- Terrestrial Energy Reports Q3 2026 Results with Increased Cash Burn and Expanded Commercial Pipeline
- Lightwave Logic Shares Drop 28% Following Q3 Results and Production Delay
- Protalix BioTherapeutics Reports Q3 2026 Revenue Growth Driven by Elfabrio Sales
- Legend Biotech Reports Q3 2026 Profitability Driven by CARVYKTI Global Expansion
- Harrow Inc. Reports Q3 2026 Revenue Growth Driven by Branded Products
- Scholar Rock Reports Q3 2026 Results Following ISEMBYLD FDA Approval
- Maze Therapeutics Reports Q3 2026 GAAP EPS of -$0.79 and Increased Net Loss
- Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026
- Bicara Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- SAB Biotherapeutics Reports Q3 2026 Financial Results and Clinical Progress
- Corvus Pharmaceuticals Provides PTCL Futility Analysis Timeline and Cash Runway Guidance
- IN8bio Reports Third Quarter Financial Results
- Elicio Therapeutics Reports Narrowed Net Loss for Third Quarter
- CytomX Therapeutics Reports Q3 2026 Financial Results and Varseta-M Clinical Updates
- Intensity Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Resumption
- Zai Lab Reports Q3 2026 Financial Results and Clinical Progress
- Viridian Therapeutics Reports Q3 2026 Results Driven by Lumvoa Commercial Launch
- Arvinas Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Stoke Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Progress
- Tesla Third-Quarter Operating Profit Declines Amid Surging R&D Spending
- Kymera Therapeutics Reports Q3 2026 Results and Positive Phase I Data for KT-579
- Viking Therapeutics Reports Q3 2026 Financial Results and Positive Obesity Pipeline Data
- Viking Therapeutics Reports Increased Q3 Net Loss Driven by Rising R&D Expenses
- Nautilus Biotechnology Reports Q3 2026 Results and Raises Annual Revenue Guidance
- Zura Bio Reports Third Quarter 2026 GAAP EPS of -$0.20
- New Horizon Aircraft Reports Q1 2027 Earnings, Highlights R&D Progress and Liquidity
- BioMarin Incurs $283M IPR&D Expense Impacting Q3 Earnings
- Regeneron Announces Earnings Impact from Expanded Collaboration with Sanofi
- Ionis Pharmaceuticals Stock Falls Over 40% This Year Despite Analysts' Bullish Outlook
- Evogene Reports Q2 2026 Earnings: Improved Financials and Strategic Shift
- PolyPid Reports Q2 2026 Earnings, Highlights FDA Priority Review and Partnership with Azurity
- Annexon Reports Q2 2026 Financials and Clinical Trial Updates
- BridgeBio Reports Q2 2026 Earnings: Revenue Growth and Regulatory Milestones
- Wave Life Sciences Reports Q2 2026 Financial Results and Clinical Progress
- Rakovina Therapeutics Reports Q1 Results with Increased R&D Expenses and Improved Cash Position
- Lexicon Reports Q1 2026 Earnings: Revenue Surpasses $21M Driven by Milestone Payments
- Zai Lab Reports Q1 2026 Earnings with Revenue Decline and R&D Growth
- Amylyx Pharmaceuticals Reports Q1 2026 Financial Results and Pipeline Updates
- Daré (DARE) Q4 2025 Earnings Call Summary
- Belite Bio (BLTE) Q1 2026 Earnings Report Highlights Key Developments
- Palisade Bio Reports Q1 2026 Results with Increased R&D Expenses
- Codexis Reports Q1 2026 Earnings: Revenue Doubles and Net Loss Narrows
- Nektar Therapeutics Q1 2026 Earnings Call Summary
- Vontier Reports Q1 2026 Earnings and Financial Performance
- Alkermes Reports Q1 2026 Earnings with Strong Sales Growth and Increased Expenses
- Sensei Biotherapeutics (SNSE) Acquires Faeth Therapeutics and Secures $200M Financing
- BioMarin Reports Q1 2026 Earnings with Revenue Growth and Guidance Update
- Travere Therapeutics Reports Q2 2025 Earnings with Strong Sales Growth
- Karyopharm (KPTI) Reports Q1 2025 Earnings with Revenue Decline and Guidance Update